BioSpace News Archive

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced preliminary financial results for the fourth quarter and full-year 2020, with U.S. revenues expected to reflect a growth range of 7% to 8%.

Veristat, a scientific-minded global clinical research organization, announced the launch of business operations in Spain and the appointment of Montserrat Barceló Riera, M.D. as Vice President, Europe.

ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, announced it has completed the separation of its Parexel Informatics and Medical Imaging business.

The global preimplantation genetic testing market is projected to gain traction for analysing minor disabilities along with other serious ailments for instance cancer.

Ear tubes are small cylinders inserted into the middle ear to allow air via the eardrum (tympanic membrane). These can also be referred as tympanostomy tubes, myringotomy tubes, ventilation tubes, or pressure equalization (PE) tubes.

The choice of embryo transfer catheters occupies a crucial role in the success rate of assisted reproduction of IVF.

The expansion of the global neurothrombectomy devices market is estimated to be driven by increasing cases of acute ischemic stroke across the globe.

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, announces that it has received MHRA and Research Ethics Committee approvals to initiate the gene therapy clinical trial in the United Kingdom with LYS-GM101 for the treatment of GM1 gangliosidosis, a serious, pediatric, life threatening disease.

BioInvent International AB announces it has restructured a clinical development agreement with Cancer Research UK, the world’s leading cancer charity, for its unique anti-FcγRIIB antibody, BI-1206.